Over the next five years, Dr. Basu Eye Hospital and Ayurvedic eye care provider Jagat Pharma intend to construct five more hospitals as part of their expansion. With Bangalore and Maharashtra as the first targets, this expansion attempts to increase patient access to their specialized eye care throughout metro cities. They currently operate two hospitals in Delhi and Bareilly.
Treatments at the facility combine contemporary diagnostics with traditional Ayurvedic therapy. They assert that their treatment can treat a wide range of eye conditions, such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts (if the maturity is up to 70%).
The founder of Dr. Basu Eye facility and Jagat Pharma, Dr. Mandeep Singh Basu, commented on this, saying, “We will be funding the expansion ourselves, without needing investors as the cost for opening a new hospital is not that high because we purchase our own machinery.” The entire apparatus needed for diagnostics typically costs around 50 lakh rupees, while the cost of the infrastructure might reach up to 25 lakh rupees. Therefore, the total cost to open a hospital is approximately one crore rupees. Our hospital is not large-scale because we don’t do any surgery. Our primary area of focus is optometry (OPT), which allows patients to visit us for a diagnostic, receive treatment, and then go. The price is therefore within that range.
When compared to both modern medical treatments and traditional procedures, the hospital asserts that the expenses of its therapies are much lower. For example, Dr. Basu Eye Hospital provides a 5 to 6-month treatment plan for about 20 to 25,000 rupees, without the necessity for surgery given the disease’s up to 70% maturity. Cataract procedures normally cost between 50,000 and 1 lakh rupees.
“Our hospitals have treated a significant number of patients over the past years, with around 80 to 90 patients visiting daily,” Basu continued while discussing their future ambitions. Our development ambitions also involve expanding the hospital’s global reach, since patients in other countries have already expressed interest in our treatments, and the hospital presently exports its goods to a few other nations. Because so many people travel there for treatment, the Middle East is a specific target market.
Entod Pharmaceuticals creates human insulin eye drops to cure corneal eye disease. Ministry authorizes investigation into Apollo Hospitals. Hospital growth and new business scale-up to generate gains for Apollo Cash-for-Kidneys scam. States will be consulted by the Health Ministry over standardizing healthcare expenditures.
Dr. Basu also disclosed that their specialty is treating uncommon diseases for which traditional medicine has no treatment, such as color blindness. They assert that their Ayurvedic remedies have enabled patients to reclaim their vision and pursue previously unattainable jobs.
Apart from expanding into new locations, Dr. Basu’s Hospital is also emphasizing enhancing its internet visibility. Acknowledging the increasing trend of e-commerce, the hospital intends to introduce novel items and offer its current therapies for online purchase. They think that this will facilitate patients’ access to their particular brand of Ayurvedic eye treatment worldwide.
SOURCE:
TIMES OF INDIA
